期刊文献+

经会阴^(125)I粒子组织间植入治疗局限性前列腺癌临床研究(附10例报告) 被引量:7

Clinical analysis of permanent transperineal ^(125)I seeds implantation for localized prostate cancer under transrectal ultrasound guidance(report of 10 cases)
下载PDF
导出
摘要 目的探讨经直肠超声(TRUS)引导下经会阴125I粒子永久性组织间植入治疗局限性前列腺癌(PCa)的临床疗效。方法对10例临床局限性前列腺癌患者采用TRUS下经会阴125I粒子永久性组织间植入的治疗情况进行回顾性研究。结果10例患者手术均成功,并发症少,术后3月内PSA均下降到正常值以下,随访9-38个月,PSA≤0.2 ng/mL,均无生化失败,均存活。结论125I粒子永久性组织间植入治疗局限性前列腺癌的临床疗效好,生化失败少,远期并发症少,生活质量高,是治疗局限性前列腺癌的良好方案。 Objective To discuss the clinical curative effect of permanent transperineal ^125I seeds implantation for localized prostate cancer. Methods ^125I seeds were implanted transperineal permanently under transrectal ultrasound (TRUS) guidance in 10 patients with localized prostate cancer. Then the effect was analysed retrospectively. Results The surgery was successfully performed in all 10 cases with few complications. PSA fell to 4 ng/mL within 3 months, and 9 to 38 months of follow-up found no PSA progression (PSA≤0. 2 ng/mL in all cases). Conclusion Permanent transperineal ^125I seeds implantation in localized prostate cancer achieves a good clinical effect, with less failure of PSA and few complications. It can be a favorable choice for localized prostate cancer.
出处 《现代泌尿外科杂志》 CAS 2007年第2期101-103,共3页 Journal of Modern Urology
基金 江苏省135医学重点学科基金(No.RC2001002) 南京市医学重点科技发展项目(No.ZKX0111)
关键词 ^125I 前列腺癌 组织间植入 ^125I prostate cancer brachytherapy
  • 相关文献

参考文献11

  • 1Nath R,Anderson LL,Luxton G,et al.Dosimetry of interstitial brachytherapy sources:Recommendations of the AAPM Radiation Therapy Committee Task Group No.43[J].Med Phys,1995,22:209-233.
  • 2吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社,2004.589-591.
  • 3Ling CC.Permanent implants using Au-198,Pd-103 and I-125:Radiobiological considerations based on the linear quadratic model[J].Int J Radiat Oncol Biol Phys,1992,23:81-87.
  • 4Nag S,Ribovich M,Cai JZ,et al.Palladium-103 vs.Iodine-125 brachytherapy in the dunning-PAP rat prostate tumor[J].Endocuriether/Hypertherm Oncol,1996,12:119-124.
  • 5Nag S,Beyer D,Friedland J,et al.American Brachytherapy Society(ABS) recommendations for transperineal permanent brachytherapy of prostate cancer[J].Int Radiat Oncol Biol Phys,1995,153:1020-1025.
  • 6Scardino P.Update:NCCN prostate cancer clinical practice guidelines[J].Journal of National Comprehensive Cancer Network,2005,3:29-33.
  • 7王俊杰,黄毅,冉维强,朱丽红,刘江平,白静,葛辉玉.放射性^(125)I粒子植入治疗睾丸切除术后复发性前列腺癌[J].肿瘤防治杂志,2003,10(9):962-964. 被引量:6
  • 8Kwok Y,Dibiase SJ,Amin PP,et al.Risk group stratification in patients undergoing permanent 125I prostate brachytherapy as monotherapy[J].Int J Radiation Oncology Bio Phys,2002,53:588-594.
  • 9Ragde H,Blasko JC,Grimm PD,et al.Brachytherapy for clinically localized prostate cancer:result at 7-and 8-year follow-up[J].Sumin Surg Oncol,1997,13:438-443.
  • 10Ragde H,Elgamal AA,Snow PB,et al.Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized,low to high Gleason grade prostate carcinoma[J].Cancer,1998,83:989-1001.

共引文献1434

同被引文献61

  • 1黄毅,马潞林,王俊杰,冉维强.^(125)I放射粒子植入结合雄激素全阻断治疗中晚期前列腺癌[J].中国老年学杂志,2005,25(3):267-268. 被引量:4
  • 2王国民,徐志兵,朱延军,徐叶青,陈绍亮,曾昭冲,程文英.^(125)I放射性粒子永久植入治疗前列腺癌[J].中华泌尿外科杂志,2005,26(4):263-266. 被引量:18
  • 3KWOK Y, DIBIASE SJ, AMIN PP, et al. Risk group stratification in patients undergoing permanent ^125I prostate rachytherapy as monotherapy [J]. Int J Radiat Oncol Biol Plays, 2002, 53: 588-594.
  • 4BLASKO JC, GRIMM PD, SYLVESTER JE, et al. Palladium-103 brachytherapy for prostate carcinoma [J]. Int J Radiat Oncol Biol Phys, 2000, 46:839-850.
  • 5RAGDE H, ELGAMAL AA, SNOW PB, et al. Ten year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma [J]. Cancer, 1998, 83: 989-1001.
  • 6AILEEN BC, ANTHONY VD, BRIDGET AN, et ah Patient and treatment factors associated with complications after prostate brachytherapy [J]. J Clin Onco, 2006, 24:5298-5304.
  • 7Grossfeld GD, Uzair B, Hary C, et al. Intermittent Androgen Deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer [J]. Urology, 2001, 58: 240-245.
  • 8Norderhang I, Dahl O, Heikkila Reino, et al. Brachytherapy for prostate cancer: A systematic review of clinical and cost effectiveness [J]. Euro Urol, 2003, 44: 40-46.
  • 9KWO K Y, DIBIASE SJ, AMIN PP, et al. Risk group st ratification in patients undergoing permanent 1251 prostate rachyt herapy as monot hemp y [J]. Int J Radiat Oncol Biol Phys, 2002, 53: 588-594.
  • 10Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects [J]. J Urol, 1998, 160 (4): 1220-1229.

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部